JP2024521364A5 - - Google Patents

Info

Publication number
JP2024521364A5
JP2024521364A5 JP2023574560A JP2023574560A JP2024521364A5 JP 2024521364 A5 JP2024521364 A5 JP 2024521364A5 JP 2023574560 A JP2023574560 A JP 2023574560A JP 2023574560 A JP2023574560 A JP 2023574560A JP 2024521364 A5 JP2024521364 A5 JP 2024521364A5
Authority
JP
Japan
Prior art keywords
antigen
virus
recombinant vaccinia
pharmaceutical composition
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521364A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030297 external-priority patent/WO2022256188A1/en
Publication of JP2024521364A publication Critical patent/JP2024521364A/ja
Publication of JP2024521364A5 publication Critical patent/JP2024521364A5/ja
Pending legal-status Critical Current

Links

JP2023574560A 2021-06-04 2022-05-20 組換えワクシニアウイルスにより免疫応答を誘導するための方法および組成物 Pending JP2024521364A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163202295P 2021-06-04 2021-06-04
US63/202,295 2021-06-04
PCT/US2022/030297 WO2022256188A1 (en) 2021-06-04 2022-05-20 Methods and composition for inducing an immune response by a recombinant vaccinia virus

Publications (2)

Publication Number Publication Date
JP2024521364A JP2024521364A (ja) 2024-05-31
JP2024521364A5 true JP2024521364A5 (https=) 2025-05-09

Family

ID=82116005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574560A Pending JP2024521364A (ja) 2021-06-04 2022-05-20 組換えワクシニアウイルスにより免疫応答を誘導するための方法および組成物

Country Status (4)

Country Link
US (1) US20240240205A1 (https=)
EP (1) EP4346895A1 (https=)
JP (1) JP2024521364A (https=)
WO (1) WO2022256188A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells

Similar Documents

Publication Publication Date Title
Hanke et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
US10912827B2 (en) Means and methods for treating HBV
JP2023512519A5 (https=)
US10059747B2 (en) Crimean-congo haemorrhagic fever virus antigenic composition
US7273605B2 (en) Vaccine
US6641816B1 (en) Use of poxviruses as enhancer of specific immunity
JP2020528911A (ja) 異種ｒｅｐＲＮＡ免疫化のための方法および組成物
WO2021207848A1 (en) Mers-cov vaccine
CN108126204A (zh) 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法
EP0913157B1 (en) A composite vaccine which contains antigen, antibody and recombinant dna and its preparing method
JP2024521364A5 (https=)
US20220275346A1 (en) Hantavirus antigenic composition
CN110382518B (zh) 用于血清型a型口蹄疫病毒的嵌合疫苗
US20150359877A1 (en) Viral Vaccine Vectors
US20110064769A1 (en) Vv promoter-driven overexpression of recombinant antigens
WO1998046263A1 (en) Saponin adjuvants in combination with dna vaccination
CN114560917A (zh) SARS-CoV-2编码蛋白来源的T细胞表位多肽TFKVSIWNL及其应用
RU2362586C2 (ru) Фармацевтические композиции для терапевтического применения
CN111012903A (zh) 一种诱导粘膜定居性记忆t细胞形成及增殖的方法
Liu et al. Use of novel DNA vectors and immunologic adjuvants in HIV vaccine development
US20250134984A1 (en) Development of mosaic vaccines against foot and mouth disease virus serotype asia
US20220118081A1 (en) HIV vaccine regimens
JP7454320B2 (ja) アジュバントとしての腫瘍溶解性ウイルス
Zrelkin et al. Study of the protective properties of immunodominant proteins of orthopoxviruses in various methods of immunization
KR101059721B1 (ko) 면역원성 조성물 및 의약